Media Coverage

Steve Rusckowski, Chairman and CEO of Quest Diagnostics, discusses opening a highly automated diagnostic testing facility in New Jersey.

Meg Tirrell joins The Exchange with Quest Diagnostics CEO Steve Rusckowski to discuss the future of Covid testing. As the flu and cold seasons return, Rusckowski says, he expects more people will turn up to Covid testing when they present symptoms that are similar to those of Covid, the flu and the common cold.

Laboratory testing is the backbone of many clinical decisions. Laboratory stewardship helps ensure testing is used for the right patients when it is truly needed. By Lee Hilborne, MD, MPH, Senior Corporate Medical Director, Quest Diagnostics.

An interview with Steve Rusckowski, chairman, chief executive officer and president of Quest Diagnostics. In 2020 the company launched Quest for Health Equity (Q4HE), an over $100 million initiative focused on addressing inequities in health care that affect underserved populations across the U.S. Quest serves half of the hospitals and one-third of the U.S. population annually. The company provides results for nearly two million tests daily, ranging from routine testing to breakthrough genetic testing.

U.S. health regulators authorized the use of the first artificial-intelligence tool designed to help doctors diagnose prostate cancer. The tool, Paige Prostate from New York startup Paige.AI Inc., analyzes digital scans of prostate biopsy slides and compares them against data sets of cell and tissue patterns previously identified as indicators of tumors. Quest Diagnostics Inc., which operates medical testing labs across the U.S., has tested Paige Prostate at its AmeriPath Inc. pathology unit and plans to use the software across various sites as soon as October, said Kristie Dolan, general manager of Quest’s oncology franchise operation.